# Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

> **NCT07264517** · PHASE2 · RECRUITING · sponsor: **Instituto Grifols, S.A.** · enrollment: 100 (estimated)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** GRF312 5%
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT07264517
- **Lead sponsor:** Instituto Grifols, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-11-14
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264517, "Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07264517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*